A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
A Clinical Trial for a Rare Pancreatic Cancer
Allison Lippman Kuban was trying to tolerate a difficult chemotherapy regimen when a mutation was found that qualified her for a clinical trial.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
The Positive Impact of a Pancreatic Cancer Clinical Trial
Richard Blish was a healthy, athletic 67-year-old when he developed symptoms of pancreatic cancer. His daughter steered him to a clinical trial for treatment.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
Embracing Optimism
Laurie MacCaskill is a long-term survivor of pancreatic cancer. She followed a personalized treatment plan, and focused her energy on remaining optimistic.
Chemotherapy to Survive; Fitness to Thrive
Mike Levine switched oncologists to find chemotherapy that works on his pancreatic cancer. After that he was able to compete in the Ironman Triathlon.
Chemoradiation Before Tumor Removal to Lessen Possible Post-Surgical Disease
A clinical trial examines the effectiveness of presurgical chemotherapy and radiation in making cancer-free margins after tumor removal.
